Comparison of Shoulder Kinematics and Muscle Activation of Female Elite Handball Players With and Without Pain-An Explorative Cross-Sectional Study.

Non-traumatic shoulder injuries are common in team handball. However, many athletes continue to throw, despite pain in the shoulder. This study investigated upper body kinematics and muscle activation while throwing in female elite handball players with and without shoulder pain. Thirty female elite team handball players, 15 with pain (age 22.2 ± 2.9 yrs.) and 15 without pain (age 20.4 ± 2.6 yrs.) performed five standing throws in which joint kinematics and muscle activity were measured in the following muscles: pectoralis major, infraspinatus, serratus anterior, latissimus dorsi, and upper-, middle-, and lower trapezius. The main findings revealed that peak joint angles and angular velocities were not different between groups; however, group differences were observed in earlier timing of position and longer time spent in maximal shoulder extension and external shoulder rotation in the pain group compared with the no pain group. The pain group also revealed a significant lower muscle peak activity in the serratus anterior during the cocking phase compared to the no pain group. After the cocking phase and at ball release, the groups had similar activation. In conclusion, the present study showed group differences in appearance and time spent in maximal humerus extension and external rotation and a different serratus anterior muscle peak activity between elite handball players playing with and without shoulder pain, which are identified as possible mechanisms of adaptation to avoid pain.

Sudden unexpected death in epilepsy: is death by seizures a cardiac disease?

RESULTS: Sudden unexpected death in epilepsy (SUDEP) gains more and more acknowledgment across the various interdisciplinary fields. Accordingly, we performed in a prospective setting a case-control study of all SUDEP cases in a well-defined part of Denmark (Northern Jutland), between January 1998 and September 2000. We attempted to look into the cardiopathologic mechanism behind this phenomenon by assessing the degree of myocardial fibrosis in SUDEP patients versus controls. The histologic evaluation was possible in 65% of the cases (15/23) whose death was attributed to SUDEP and in 71% (15/21) of controls. Forty percent of the SUDEP cases (6/15) presented several foci of fibrotic changes in the deep and subendocardial myocardium in contrast to 1 control (6.6%, P = 0.03). None of the subjects from the SUDEP group showed fibrotic changes in their conduction system as compared with 1 control (6.6%). The quantitative evaluation of fibrosis demonstrated a trend toward more fibrosis in the deep and subendocardial myocardium of the SUDEP cases. Forty percent of cases in the SUDEP group were men (6/15), characteristically young at time of death (mean age 38 years) and with a late epilepsy onset (mean age 21 years). Antemortem, 73% of the SUDEP patients (11/15) had experienced infrequent seizures (self-reported). We conclude that the SUDEP cases displayed significant fibrosis of the myocardium when this was assessed by qualitative means. This fibrosis may be the consequence of myocardial ischemia as a direct result of repetitive epileptic seizures, which, associated with the ictal sympathetic storm, may lead to lethal arrhythmias.

Randomized, concentration-controlled trial of topiramate in refractory focal epilepsy.

OBJECTIVE: To establish the concentration response of topiramate in patients with refractory focal epilepsy. METHODS: Sixty-five patients with more than eight seizures during an 8-week baseline were randomized to three prespecified plasma levels (low, 6 micromol/L [2 mg/L]; medium, 31 micromol/L [10.5 mg/L]; and high, 56 micromol/L [19 mg/L]). Topiramate treatment was titrated to one of the prespecified plasma levels during an 8-week titration period, followed by a 12-week observation period. RESULTS: The overall median (25th to 75th percentile) reduction in seizures during the observation compared with baseline was 50% (9.5 to 90%). In the individual groups, the median reduction was as follows: low, 39% (13 to 70%); medium, 85% (41 to 96%); and high, 39% (2.0 to 81%). The primary outcome of the trial was the comparison of seizure reduction (Mann-Whitney U test) between the low and the medium group (p = 0.03). Comparisons between the other groups were as follows: medium vs high (p = 0.05) and low vs high (p = 0.81). Psychiatric adverse events and adverse events related to the CNS were the most frequently encountered. Most adverse events showed concentration response, particularly between low and medium levels. CONCLUSIONS: Patients assigned to the medium plasma level (31 micromol/L [10.5 mg/L]) had the best seizure outcome. Patients in the medium and high groups experienced more adverse events than patients in the low group. Optimal treatment response is thus most likely found at plasma concentrations higher than 6 micromol/L (2 mg/L), but no further increase in efficacy seems to occur at concentrations above 31 micromol/L (10.5 mg/L).

Higher androgens and weight gain with valproate compared with lamotrigine for epilepsy.

BACKGROUND: Valproate is used widely for the treatment of epilepsy but has been associated with hyperandrogenism, hyperinsulinemia, and dyslipidemia. The mechanism for these associations is unknown, but they have been hypothesized to be secondary to valproate-associated weight gain. This study was conducted to test the hypothesis that the antiepileptic drug lamotrigine, which also has a broad spectrum of anti-seizure efficacy, would not be associated with endocrine abnormalities and would not cause weight gain. OBJECTIVE AND METHODS: This open-label, cross-sectional study compared (1) endocrine and lipid measures during the early follicular phase of the menstrual cycle; (2) prevalence of menstrual disorders (from patient diaries recorded over three cycles); and (3) body weight of women with epilepsy on lamotrigine monotherapy (n=119) with those on valproate monotherapy (n=103) for <5 years. RESULTS: Mean total serum testosterone and androstenedione levels were higher (P<0.02) in the valproate group compared with the lamotrigine group. More lamotrigine patients (87%) than valproate patients (77%) reported regular menstrual cycles at the Screening Visit. The prevalence of anovulation did not differ between lamotrigine and valproate. Mean HDL cholesterol levels were higher (P<0.01) with lamotrigine compared with valproate as were LDL and total cholesterol levels (P<0.05). Mean total insulin levels did not significantly differ between the groups. Whereas mean body weight in lamotrigine patients did not differ between the time lamotrigine treatment was initiated and the Study Visit, mean weight in valproate patients increased by 3.7 kg. CONCLUSIONS: Compared with lamotrigine monotherapy, valproate monotherapy was associated with weight gain and higher androgen levels in women with epilepsy. These data suggest that the hyperandrogenism observed in some women using valproate for epilepsy may be secondary to drug therapy. Lamotrigine monotherapy may be more appropriate than valproate for women in whom reproductive endocrine or metabolic abnormalities are potential concerns, i.e. women with concerns about weight gain, diabetes, hirsutism, polycystic ovary syndrome, menstrual dysfunction or infertility.

Quantitative Neuropathology in Electrically Induced Generalized Convulsions.

A critical review of the neuropathology associated with seizures is presented, with special reference to the damage to the brain claimed to result from electroconvulsive treatment (ECT). From the point of view of neuron loss, there is no evidence that single seizures (convulsions), even if repeated, result in this type of damage to the brain, which is the only definitely irreversible kind. Pitfalls of the methods of investigation available in neuropathology are described to support this statement. Basic differences between epileptic seizures and induced seizures are emphasized in relation to neuron loss in epilepsy.